ProShare Advisors LLC Sells 732 Shares of BioNTech SE (NASDAQ:BNTX)

ProShare Advisors LLC reduced its stake in shares of BioNTech SE (NASDAQ:BNTX) by 10.8% in the second quarter, according to its most recent filing with the SEC. The fund owned 6,053 shares of the company’s stock after selling 732 shares during the period. ProShare Advisors LLC’s holdings in BioNTech were worth $486,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Harding Loevner LP bought a new position in shares of BioNTech during the 4th quarter valued at about $410,984,000. Candriam S.C.A. increased its stake in BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after purchasing an additional 418,695 shares during the period. SG Americas Securities LLC lifted its position in BioNTech by 610.5% in the first quarter. SG Americas Securities LLC now owns 70,143 shares of the company’s stock valued at $6,471,000 after purchasing an additional 60,270 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of BioNTech by 51.3% during the first quarter. Acadian Asset Management LLC now owns 111,398 shares of the company’s stock valued at $10,275,000 after purchasing an additional 37,792 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of BioNTech by 85.9% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 68,428 shares of the company’s stock worth $6,312,000 after buying an additional 31,615 shares during the period. 15.52% of the stock is owned by institutional investors.

BioNTech Price Performance

Shares of BNTX opened at $118.77 on Tuesday. The firm’s 50-day simple moving average is $94.54 and its two-hundred day simple moving average is $91.61. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The stock has a market cap of $28.23 billion, a PE ratio of 237.54 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The company had revenue of $128.70 million during the quarter, compared to analysts’ expectations of $134.98 million. BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The business’s quarterly revenue was down 23.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.86) EPS. Analysts anticipate that BioNTech SE will post -2.87 earnings per share for the current fiscal year.

Analyst Ratings Changes

BNTX has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft raised their target price on BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, September 19th. TD Cowen cut their price objective on BioNTech from $98.00 to $85.00 and set a “hold” rating on the stock in a research report on Tuesday, August 6th. UBS Group upped their target price on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. raised shares of BioNTech from an “underweight” rating to a “neutral” rating and boosted their price objective for the company from $91.00 to $125.00 in a research report on Monday, September 16th. Finally, HSBC raised shares of BioNTech from a “hold” rating to a “buy” rating in a research report on Friday, August 2nd. Five investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $127.15.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.